In Novo Nordisk’s legal fight against dozens of U.S. pharmacies and companies selling cheaper copies of its weight-loss drug ...

STORY: Novo Nordisk is ramping up lawsuits against U.S. companies selling cheaper versions of its weight-loss drug Wegovy. But one firm remains conspicuously absent: Hims & Hers.This telehealth ...

Hims & Hers Health ( NYSE: HIMS) shares traded lower for the second straight session on Tuesday after the telehealth firm’s ...

Novo Nordisk , maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish ...

Hims & Hers Health Inc. (NYSE: HIMS) plunged 13.1% in Tuesday pre-market after the digital health company reported ...

Shares of Hims & Hers tumbled 12% in after-hours trading Monday after the company's second-quarter revenue missed Wall Street ...

This article covers key health news including Primary Health Properties securing a takeover bid for Assura, Novo Nordisk's ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

Hims & Hers Health stock fell as much as 5% early Tuesday after the company reported revenue late Monday that fell shy of ...

Hims & Hers (NYSE:HIMS) stock slips as U.S. lawmakers seek FDA action against copycat versions of weight loss drugs from Novo (NVO) and Lilly (LLY). Read more here.